Rapid development of an efficacious swine vaccine for novel H1N1

Ryan Vander Veen; Kurt Kamrud; Mark Mogler; Alan T. Loynachan; Jerry McVicker; Peter Berglund; Gary Owens; Sarah Timberlake; Whitney Lewis; Jonathan Smith; D. L.Hank Harris

doi:10.1371/currents.RRN1123

Rapid development of an efficacious swine vaccine for novel H1N1

Ryan Vander Veen, Kurt Kamrud, Mark Mogler, Alan T. Loynachan, Jerry McVicker, Peter Berglund, Gary Owens, Sarah Timberlake, Whitney Lewis, Jonathan Smith, D. L.Hank Harris

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Recombinant hemagglutinin (HA) from a novel H1N1 influenza strain was produced using an alphavirus replicon expression system. The recombinant HA vaccine was produced more rapidly than traditional vaccines, and was evaluated as a swine vaccine candidate at different doses in a challenge model utilizing the homologous influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily gain when compared to non-vaccinated control animals. These data demonstrate that the swine vaccine candidate was efficacious at all of the evaluated doses.

Original language	English
Article number	ecurrents.RRN1123
Journal	PLoS Currents
Issue number	OCT
DOIs	https://doi.org/10.1371/currents.RRN1123
State	Published - 2009

ASJC Scopus subject areas

Medicine (miscellaneous)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/currents.RRN1123

Cite this

@article{e2e850969d404e5799e8e233b49c70f4,

title = "Rapid development of an efficacious swine vaccine for novel H1N1",

abstract = "Recombinant hemagglutinin (HA) from a novel H1N1 influenza strain was produced using an alphavirus replicon expression system. The recombinant HA vaccine was produced more rapidly than traditional vaccines, and was evaluated as a swine vaccine candidate at different doses in a challenge model utilizing the homologous influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily gain when compared to non-vaccinated control animals. These data demonstrate that the swine vaccine candidate was efficacious at all of the evaluated doses.",

author = "Veen, {Ryan Vander} and Kurt Kamrud and Mark Mogler and Loynachan, {Alan T.} and Jerry McVicker and Peter Berglund and Gary Owens and Sarah Timberlake and Whitney Lewis and Jonathan Smith and Harris, {D. L.Hank}",

year = "2009",

doi = "10.1371/currents.RRN1123",

language = "English",

number = "OCT",

}

TY - JOUR

T1 - Rapid development of an efficacious swine vaccine for novel H1N1

AU - Veen, Ryan Vander

AU - Kamrud, Kurt

AU - Mogler, Mark

AU - Loynachan, Alan T.

AU - McVicker, Jerry

AU - Berglund, Peter

AU - Owens, Gary

AU - Timberlake, Sarah

AU - Lewis, Whitney

AU - Smith, Jonathan

AU - Harris, D. L.Hank

PY - 2009

Y1 - 2009

N2 - Recombinant hemagglutinin (HA) from a novel H1N1 influenza strain was produced using an alphavirus replicon expression system. The recombinant HA vaccine was produced more rapidly than traditional vaccines, and was evaluated as a swine vaccine candidate at different doses in a challenge model utilizing the homologous influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily gain when compared to non-vaccinated control animals. These data demonstrate that the swine vaccine candidate was efficacious at all of the evaluated doses.

AB - Recombinant hemagglutinin (HA) from a novel H1N1 influenza strain was produced using an alphavirus replicon expression system. The recombinant HA vaccine was produced more rapidly than traditional vaccines, and was evaluated as a swine vaccine candidate at different doses in a challenge model utilizing the homologous influenza A/California/04/2009 (H1N1) strain. Vaccinated animals showed significantly higher specific antibody response, reduced lung lesions and viral shedding, and higher average daily gain when compared to non-vaccinated control animals. These data demonstrate that the swine vaccine candidate was efficacious at all of the evaluated doses.

UR - http://www.scopus.com/inward/record.url?scp=78649329559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649329559&partnerID=8YFLogxK

U2 - 10.1371/currents.RRN1123

DO - 10.1371/currents.RRN1123

M3 - Article

AN - SCOPUS:78649329559

SN - 2157-3999

JO - PLoS Currents

JF - PLoS Currents

IS - OCT

M1 - ecurrents.RRN1123

ER -

Rapid development of an efficacious swine vaccine for novel H1N1

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this